1. 226. Higher Doses of Adintrevimab, an Extended Half-Life Monoclonal Antibody, for the Treatment and Prevention of COVID-19: Preliminary Results from a Phase 1 Single Ascending-Dose Study. (15th December 2022) Authors: Pu, Xia; Gong, Jean; Campanaro, Ed; Narayan, Kristin; Gupta, Deepali; Engler, Frank; Copans, Amanda; Schmidt, Pete Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 633. Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19). (4th December 2021) Authors: Paguntalan, Helen; Magyarics, Zoltán; Connolly, Lynn E; Hershberger, Ellie; Narayan, Kristin; Gupta, Deepali; Ambrose, Paul G; Engler, Frank; Campanaro, Ed; Das, Anita F; Schmidt, Pete Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S420 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 633. Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19). (4th December 2021) Authors: Paguntalan, Helen; Magyarics, Zoltán; Connolly, Lynn E; Hershberger, Ellie; Narayan, Kristin; Gupta, Deepali; Ambrose, Paul G; Engler, Frank; Campanaro, Ed; Das, Anita F; Schmidt, Pete Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S420 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. MO258SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY. (29th May 2021) Authors: Suzuki, Yusuke; Mathur, Mohit; Barratt, Jonathan; Engler, Frank; Yarbrough, Jill; Sloan, Susan; Oldach, David Journal: Nephrology dialysis transplantation Issue: Volume 36(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. MO283IMPACT OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, ON TETANUS- AND DIPHTHERIA-TOXOID VACCINATION-ELICITED IMMUNE RESPONSES IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. (29th May 2021) Authors: Barratt, Jonathan; Mathur, Mohit; Suzuki, Yusuke; Engler, Frank; Yarbrough, Jill; Sloan, Susan; Oldach, David Journal: Nephrology dialysis transplantation Issue: Volume 36(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗